|
End-of-day quote
Taiwan S.E.
27/10/2026
|
5-day change | 1st Jan Change | ||
| 57.10 TWD | +0.18% |
|
+0.35% | +6.64% |
| Market Cap | 10.2B 315M 282M 261M 236M 442M 29.89B 447M 3.13B 1.24B 15.67B 1.18B 1.16B 49.68B | P/E 2024 |
12.6x | P/E 2025 | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 8.77B 270M 243M 224M 203M 380M 25.68B 384M 2.69B 1.07B 13.46B 1.01B 993M 42.69B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.29x |
| Free-Float |
44.21% | Yield 2024 |
4.52% | Yield 2025 | 3.4% |
| 1 day | +0.18% | ||
| 1 week | +0.35% | ||
| Current month | +1.42% | ||
| 1 month | +1.60% | ||
| 3 months | -0.52% | ||
| 6 months | +2.63% | ||
| Current year | +6.64% |
| 1 week | 56.7 |  | 57.4 |
| 1 month | 55.6 | | 58.3 |
| Current year | 53.55 | | 60.55 |
| 1 year | 50.18 | | 60.55 |
| 3 years | 46.55 | | 72.18 |
| 5 years | 34.86 | | 72.36 |
| 10 years | 24.86 | | 72.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tzu-Ting Fan
CEO | Chief Executive Officer | - | 30/05/2006 |
Shu Hua Chen
IRC | Investor Relations Contact | - | - |
Wei Jen Chen
PRN | Corporate Officer/Principal | - | 01/04/2001 |
| Director | Title | Age | Since |
|---|---|---|---|
Chin Tsai Fan
CHM | Chairman | - | 30/06/1967 |
Tzu-Ting Fan
CHM | Chairman | - | - |
Yuan Te Li
BRD | Director/Board Member | - | 06/06/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.18% | +0.35% | +12.36% | +3.14% | 315M | |
| +0.22% | -0.14% | +55.12% | +128.82% | 1,143B | |
| +0.91% | +3.61% | +41.21% | +84.57% | 647B | |
| -0.12% | -0.93% | +25.59% | +106.14% | 506B | |
| -1.18% | +0.36% | +50.67% | +63.03% | 384B | |
| +0.86% | -4.37% | +61.16% | +37.93% | 350B | |
| -0.17% | +1.32% | +30.03% | +51.91% | 293B | |
| -0.75% | +0.57% | +2.26% | +24.15% | 265B | |
| +0.75% | +2.05% | +53.85% | +71.25% | 242B | |
| +0.25% | +1.64% | +32.05% | +107.62% | 197B | |
| Average | -0.34% | +0.76% | +36.43% | +67.86% | 402.78B | |
| Weighted average by Cap. | -0.47% | +0.71% | +42.76% | +87.70% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 6.79B 209M 188M 174M 157M 294M 19.89B 298M 2.08B 826M 10.42B 786M 769M 33.06B | 7.02B 217M 194M 179M 163M 304M 20.57B 308M 2.15B 855M 10.78B 813M 796M 34.19B |
| Net income | 881M 27.15M 24.37M 22.5M 20.41M 38.14M 2.58B 38.61M 270M 107M 1.35B 102M 99.75M 4.29B | 928M 28.61M 25.68M 23.71M 21.5M 40.18M 2.72B 40.67M 284M 113M 1.42B 107M 105M 4.52B |
| Net Debt | -1.24B -38.35M -34.42M -31.78M -28.82M -53.86M -3.64B -54.53M -381M -151M -1.91B -144M -141M -6.05B | -1.44B -44.29M -39.75M -36.7M -33.28M -62.21M -4.21B -62.97M -440M -175M -2.21B -166M -163M -6.99B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/10/26 | TWD 57.10 | +0.18% | 306,425 |
| 22/10/26 | TWD 57.00 | +0.35% | 139,903 |
| 21/10/26 | TWD 56.80 | -0.18% | 228,324 |
| 20/10/26 | TWD 56.90 | -0.35% | 294,813 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1720 Stock
Select your edition
All financial news and data tailored to specific country editions
